ZNF366 (E5O9G) Rabbit mAb #47952
- WB
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 100 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
ZNF366 (E5O9G) Rabbit mAb recognizes endogenous levels of total ZNF366 protein. This antibody detects a non-specific band at 60 kDa in some cell lines.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Tyr57 of human ZNF366 protein.
Background
Dendritic cells (DCs) are the watchmen of the immune system, detecting a wide variety of pathogens and initiating robust immune responses. To respond to highly variable challenges, DCs have diversified into multiple phenotypical, anatomical, and functionally distinct cell types (1,2). Zinc finger protein 366 (ZNF366) was originally identified in a yeast two-hybrid screen for transcriptional regulators responding to estrogen (3,4). ZNF366 (dendritic cell (DC)-specific transcript, DC-SCRIPT) is a member of the Cys-Cys:His-His subfamily of zinc finger proteins (5). ZNF366 localizes to the nucleus and does not show transcriptional activation via transactivation assays but does interact with co-repressors (2,5). ZNF366 has been shown to be DC-specific and is expressed in myeloid DCs, plasmacytoid DCs, and Langerhans cells (5). ZNF366 knockout mice show an immune deficiency phenotype, with substantially decreased expression of the transcription factor, IRF-8 (6). Loss of function in ZNF366 has been implicated in tumor cell evasion of immune responses (7). ZNF366 represents a novel DC marker that could be involved in transcriptional repression (1,5).
- Nutt, S.L. and Chopin, M. (2020) Immunity 52, 942-956.
- Villar, J. et al. (2023) EMBO Rep 24, e56308.
- Lopez-Garcia, J. et al. (2006) Nucleic Acids Res 34, 6126-36.
- Ansems, M. et al. (2015) Breast Cancer Res Treat 149, 693-703.
- Triantis, V. et al. (2006) J Immunol 176, 1081-9.
- Zhang, S. et al. (2021) Sci Immunol 6, eabf4432. doi: 10.1126/sciimmunol.abf4432.
- Zimmermannova, O. et al. (2023) Sci Immunol 8, eadd4817.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.